The role of therapeutic apheresis in the treatment of cancer: A review

Therapeutic Apheresis

Volumn 3, Issue 1, 1999, Pages 40-49

  Lentz, M Rigdon ^a,b  

^a Columbia S Hills Medical Center ^*  (United States)

^b NONE   (United States)

Author keywords

Cancer; Immunosuppression; Ultrapheresis

Indexed keywords

CYTOKINE; FC RECEPTOR; INTERLEUKIN 1; INTERLEUKIN 6; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ANTIGEN PRESENTATION; APHERESIS; CANCER IMMUNOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW;

ANIMALS; BLOOD COMPONENT REMOVAL; HUMANS; IMMUNOSUPPRESSION; INTERLEUKIN-1; INTERLEUKIN-6; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; PROGNOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032971253     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-0968.1999.00147.x     Document Type: Review

References (88)

1. Lentz MR. Phylogeny of Oncology. J Mol Biol Ther 1990;2: 137-43.
2. Bellanti JA, Rocklin RE. Cell-mediated immune reactions. In: Bellanti JA, ed. Immunology III. Philadelphia: WB Saunders, 1985:176-88.
3. DeVita V, Hellman S, Rosenberg S. Cancer: Principles and practice of oncology. New York: Lippincott, 1993.
4. Whittaker MG, Rees K, Clark CG. Reduced lymphocyte transformation in breast cancer. Lancet 1971;1:892-3.
5. Suciu-Foca N, Buda J, McManus J, Theim J, Reemtsma K. Impaired responsiveness of lymphocytes and serum inhibitory factors in patients with cancer. Cancer Res 1973;33:2373-7.
6. Leichtenstein MR. Tuberculin reaction to tuberculosis during pregnancy. Am Rev Tuberc 1942;46:89-92.
7. Rosenstein RW, Murray JH, Cone RE, Ptak W, Iverson GM, Gershon RK. Isolation and partial characterization of antigen specific T cell factor associated with the suppression of delayed type hypersensitivity. Proc Natl Acad Sci USA 1981;78: 5821-5.
8. Baldwin RW, Price MR, Robins RA. Blocking of lymphocyte mediated cytotoxicity for rat hepatoma cells by tumor specific antigen antibody complexes. Nature (Nu Biol) 1972;238: 185-6.
9. Hellstrom KE, Hellstrom I. Lymphocyte mediated cytotoxicity and blocking serum activity to tumor antigens. Adv Immunol 1974;18:209-77.
10. Murray E, Ruygrok S, Milton GW, Hersey P. Analysis of serum blocking factors against leukocyte dependent antibody in melanoma patients. Int J Cancer 1978;21:578-87.
11. Sample WF, Gertner HR Jr, Chretein PB. Inhibition of phytohemagglutinin induced in vitro lymphocyte transformation by serum from patients with carcinoma. JNCI 1971;46:1291-7.
12. Hess AD, Gaul JA, Dawson JR. Partial purification and characterization of lymphocyte inhibitory factor (S) in ascitic fluids from ovarian cancer patients. Cancer Res 1980;40:1842-51.
13. Broder S, Waldmann TA. The suppressor cell network in cancer, Part 2. New Engl J Med 1978;299:1335-41.
14. DeLustro F, Argyris BF. Mastocytoma mediated suppression of mixed lymphocyte culture in mitogen responsiveness. Cell Immunol 1976;21:177-84.
15. Kamo I, Patel C, Kately J, Friedman H. Immunosuppression induced in vitro by mastocytoma tumor cells in cell free extracts. J Immunol 1975;114:1749-56.
16. Nelson M, Nelson DS. Macrophages and resistance to tumors. Inhibition of delayed type hypersensitivity reactions by tumor cells and by soluble products affecting macrophages. Immunology 1978;34:277-90.
17. McCarthy RE, Coffin JN, Gates SL. Selective inhibition of the secondary immune response to mouse skin allographs by cell free Ehrlich ascites carcinoma fluid. Transplantation 1968; 6:737.
18. Murgita RA, Tomasi TB Jr. Suppression of the immune response by alpha fetoprotein on the primary and secondary antibody responses. J Exp Med 1975;141:269-86.
19. Vanky F, Klein E, Stjernsward J, Trempe G. Lymphocyte stimulation by autologous tumor cells in the presence of serum from the same patient or from healthy donors. Int J Cancer 1975;16:850-60.
20. Kalish R, Brody NI. Increased incidence of tumor takes to B 16 melanoma on C57BL/6J mice injected with B 16 products. J Invest Dermatol 1980;75:275-8.
21. Yachnin S, Lester E. Inhibition of human lymphocyte transformation by human alpha fetoprotein (HAFP); comparison of fetal and heptoma (HAFP) and kinetic studies in vitro immunosuppression. Clin Exp Immunol 1976;26:484-90.
22. Werkmeister J, Phillips G, McCarthy W, Hersey P. Suppressor cell activity in melanoma patients. II. Concavalin A induced suppressor cells in relation to tumor growth and suppressor cells subsets. Int J Cancer 1981;28:11-5.
23. Lentz MR, Gatanaga T, Wang C. Purification and characterization of inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients. Proc Natl Acad Sci USA 1990;87:8781-4.
24. Kasakura S. Heterogeneity of blastogenic factors produced in vitro by antigenetically stimulated and unstimulated lymphocytes. J Immunol 1970;105:1162-7.
25. Gleichner N, Siegel I. Common denominators of pregnancy malignancy. In: Gleichner N, ed. Reproductive immunology. New York: Liss, 1981:229-56.
26. Muchmore AV, Decker JM. Uromodulin: A unique 85 kilodalton immunosuppressant glycoprotein isolated from the urine of pregnant women. Science 1985;229:479-81.
27. Olsson I, Lantz M, Nillson E. Isolation and characterization of tumor necrosis factor binding protein from urine. Eur J Hematol 1989;42:270-5.
28. Lentz MR, Gatanaga T, Granger GA. Identification of TNF-LT blocking factor in serum and ultrafiltrates of human cancer patients. Lymphok Res 1990;9(2):225-9.
29. Schall TJ, Lentz MR. Molecular cloning and expression of receptor for human tumor necrosis factor. Cell 1990;61: 361-70.
30. Beutler B, Cerami A. Tumor necrosis, cachexia, shock, and inflammation: A common mediator. Ann Rev Biochem 1988; 57:505-18.
31. Vilcek J, Lee TH. Tumor necrosis factor: New insights into the molecular mechanisms of its multiple actions. J Biol Chem 1991;26:7313-6.
32. Dembic Z, Loetscher H, Gubler U, Pan YC, Lahm HW, Gentz R, Brockhaus M, Lesslauer W. Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences. Cytokine 1990;2(4):231-7.
33. Tartaglia LA, Geoddel DV. Two TNF receptors. Immunol Today 1992;13:151-3.
34. Loetscher H, Pan YC, Lahm HW, Gentz R, Brockhaus M, Tabuchi H, Lesslauer W. Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell 1990;20(6):351-9.
35. Seckinger P, Isaaz S, Dayer JM. Purification and biologic characterization of a specific tumor necrosis factor alpha inhibitor. J Biol Chem 1989;2640(20):11966-73.
36. Engelman H, Novick D, Wallach D. Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem 1990;265(3):1531-6.
37. Aderka D, Engelmann H, Shemer-Avni Y, Hornik V, Galil A, Sarov B, Wallach D. Variation in serum levels of the soluble TNF receptors among healthy individuals. Lymphok Cytok Res 1992;11(3):157-59.
38. Chouaib S, Branellec D, Buurman WA. More insights into the complex physiology of TNF. Immunol Today 1991;12(5): 141-2.
39. Austgulen R, Liabakk NB, Brockhaus M, Espevik T. Soluble TNF receptors in amniotic fluid and in urine from pregnant women. J Reprod Immunol 1992;22(2):105-16.
40. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci USA 1992;89(11):4845-9.
41. Girardin E, Roux-Lombard P, Grau GE, Suter P, Gallati H, Dayer JM. Imbalance between tumor necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcaimia. The J5 Study Group. Immunology 1992;766(1): 20-3.
42. Kalinkovich A, Engelmann H, Harpaz N, Burstein R, Barak V, Kallckman I, Wallach D, Bentwich Z. Elevated serum levels of soluble tumor necrosis factor receptors (sTNFs) in patients with HIV infection. Clin Exp Immunol 1992;89(3): 351-5.
43. Andus T, Gross V, Holstege A, Ott M, Weber M, David M, Gallati H, Gerok W, Scholmerich J. High concentrations of soluble tumor necrosis receptors in ascites. Hepatology 1992;16(3):749-55.
44. Spinas GA, Keller U, Brockhaus M. Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxinemia. J Clin Invest 1992;90(2):533-6.
45. Porteu F, Nathan C. Shedding of tumor necrosis factor receptors by activated human neutrophils. J Exp Med 1990;172(2): 590-607.
46. Pusztai L, Clouse LM, Cooper K, Starkey PM, Lewis CE, McGee JO'D. Expression of tumour necrosis factor a and its receptors in carcinoma of the breast. Br J Cancer 1994;70: 289-92.
47. Aderka D, Engelmann H, Kushtai G. Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res 1991;51:5602-7.
48. Langkopf F, Atzpodien J. Soluble tumor necrosis factor receptors as prognostic factors in cancer patients. Lancet 1994; 344:57-8.
49. Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood 1991;77:1627.
50. Sims JE, Gayle MA, Slack JL, Alderson MR, Bird TA, Giri JG, Colotta F, Re F, Mantovani A, Shamebeck K, Gabstein KH, Dower SK. Interleukin-1 signaling occurs exclusively via the type I receptor. Proc Natl Acad Sci 1993;90:6155-9.
51. Stylianou E, O'Neill LA, Rawlinson L, Edbrooke MR, Woo P, Saklatvola J. Interleukin-1 induces NF-kappa B through its type I but next its type type II receptor in lymphocytes. J Biol Chem 1992;267:15836-41.
52. Giri JG, Newton RC, Horuk R. Identification of soluble interleukin-1 binding protein in cell-free supernatants. Evidence for soluble interleukin-1 receptor. J Biol Chem 1990; 265:17416-9.
53. Symons JA, Eastgate JA, Duff GW. Purification and characterization of a novel soluble receptor for interleukin-1. J Exp Med 1991;164:1251-4.
54. Seckinger P, Lowenthal JW, Wiliamson K, Dayer JM, MacDonald JR. Inhibitor in urine of interleukin-1 activity that blocks ligand binding. J Immunol 1987;139:1546-9.
55. Mazzei GJ, Seckinger PL, Dayer JM, Shaw AR. Purification and characterization of a 26-kDa competetive inhibitor of interleukin-1. J Immunol 1990;20:683-9.
56. Hannum CJ, Wilcox CJ, Arend WP, Joslin FG, Dripps DJ, Heindal PL, Armes LG, Somner A, Eisenberg SP, Thompson RC. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 1990;343:336-40.
57. Eisenberg SP, Evan RD, Arend WP, Verderber E, Brewer MT, Hannum CH, Thompson RC. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 1990;343:341-6.
58. Dripps DJ, Brandhuber BJ, Thompson RC, Eisenberg SP. Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction. J Biol Chem 1991;266:10331-6.
59. Granowitz EV, Clark BD, Mancilla J, Dinarello CA. Interleukin-1 receptor antagonist competetively inhibits the binding of interleukin-1 to the type II interleukin-1 receptor. J Biol Chem 1991;266:14147-50.
60. Muzio M, Re F, Sironi M, Polentarutti N, Minty A, Caput D, Ferrara P, Mantovani A, Colatta F. Interleukin-1 induces the production of interleukin-1 receptor antagonist (IL-1rα) and the expression of the RNA for the introcellular (keratinocyte) form of IL-1rα in human myelomonocytic cells. Blood 1994;83(7):1738-43.
61. Janson RW, Hance KR, Arend WP. Production of IL-1 receptor antagonist by human in vitro derived macrophages. Effects of lipopolysaccharide and granulocyte-macrophage colony stimulating factor. J Immunol 1991;147:4218-23.
62. Krzesicki RF, Hatfield CA, Bienkowski MJ, McGuire JC, Winterrowed GE, Chapman DL, Berger AE, McEwan RN, Carter DB, Chosay JG, Tracey DE, Chin JE. Regulation of expression of IL-1 receptor antagonist protein on human synovial and dermal fibroblasts. J Immunol 1993;150:4008.
63. Tilg H, Trehw E, Atkins MB, Dinarello CA, Mier JW. Interleukin-6 (IL-6) as an anti-inflammatory cytokine induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p 55. Blood 1994;83:113.
64. Vannier E, Miller LC, Dinarello CA. Coordinated anti-inflammatory effects in interleukin 4: Interleukin 4 suppresses interleukin-1 production but up-regulates gene expression and synthesis of interleukin-1 receptor antagonist. Proc Natl Acad Sci 1992;89:4076-80.
65. Tilg H, Mier JW, Vogel W, Aulitzky WE, Wiedermann CJ, Vannier E, Huber C, Dinarello CA. Induction of circulating IL-1 receptor antagonist by IFN treatment. J Immunol 1993; 150:4687.
66. McColl SR, Paquin R, Menard C, Beaulien AD. Human neutrophils produce high levels of the interleukin-1 receptor antagonist in response to granulocyte/macrophage colony-stimulating factor and tumor necrosis factor alpha. J Exp Med 1992;176:593-8.
67. Wahl SM, Costa GL, Corcoran M, Wahl LM, Berger AE. Transforming growth factor-beta mediates IL-1 dependent induction of IL-1 receptor antagonist. J Immunol 1993;150: 3553-60.
68. Dinarello CA, Thompson RC. Blocking IL-1: Interleukin-1 receptor antagonist in vivo and in vitro. Immunol Today 1991; 12:404-10.
69. Dinarello CA, Wolff SM. The role of interleukin-1 in disease. New Engl J Med 1993;328:106-13.
70. Ohisson K, Bjork P, Bergenfeldt M, Hageman R, Thompson RC. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990;348:550-2.
71. Cominell F, Nast CC, Clark BD, Schindler R, Lierena R, Eysselein VE, Thompson RC, Dinarello CA. Interleukin-1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis. J Clin Invest 1990;86:972-80.
72. Ferreti M, Casini-Raggi V, Pizarro TT, Eisenberg SP, Nast CC, Cominelli F. Neutralization of endogenous IL-1 receptor antagonist exacerbates and prolongs inflammation in rabbit immune cells. J Clin Invest 1994;94:449-53.
73. Ramilo O, Saez-Lorens X, Mertsola J, Jafari H, Olsen KD, Hansen EJ, Yoshinaga M, Ohkawara S, Nariuchi H, McCrocken GH Jr. Tumor necrosis factor alpha/cachectin and interleukin-1 beta initiate meningeal inflammation. J Exp Med 1990;172:497-501.
74. Antin JH, Weinstein HJ, Guinan EC, McCarthy P, Bierer BE, Gilliland DG, Parsons SK, Ballen KK, Rimm IJ, Falzarano G, Blacedow DC, Abate L, Lebsack M, Burakoff SJ, Ferrara JLM. Recombinant interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood 1994;84:1342-8.
75. Van Snik J. Interleukin-6: An overview. Annu Rev Immunol 1990;8:253-78.
76. Hirano T, Kishimto T. Interleukin-6. In: Sporn MB, Roberts AB, eds. Peptide growth factors and their receptors. New York: Springer-Verlag, 1990:663-5.
77. Hirano T, Akira S, Taga T, Kishimoto T. Biological and clinical aspects of interleukin-6. Immunol Today 1990;11:443-9.
78. Yamasalki K, Taga T, Hirata T, Yawata T, Kawanishi Y, Zeed B, Taniguchi T, Hirano T, Kishimoto T. Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. Science 1988;241:825-8.
79. Baumann M, Baumann H, Fey GH. Molecular cloning, characterization and functional expression of the rat liver interleukin-6 receptor. J Biol Chem 1990;265:19853-62.
80. Hibi M, Murakami M, Saito M, Hirano T, Taga T, Kishimoto T. Molecular cloning and expression of an IL-6 transducer, GP130. Cell 1990;63:1149-57.
81. Schooltink H, Stoyan T, Lenz D, Schmitz H, Hirano T, Kishimoto T, Heinrich PC, Rose-John S. Structural and functional studies on the hepatic interleukin-6 receptor. Molecular cloning and overexpression in HepG2 cells. Eur J Biochem 1991; 277:659-64.
82. Nakajima T, Yamamoto S, Cheng M, Yasukawa K, Hirano T, Tokunaga T, Honda M. Soluble interleukin-6 receptor is released from receptor-bearing cell lines in vitro. Jpn J Cancer Res 1990;83:373-78.
83. Honda M, Yamamoto S, Cheng M, Yasukawa K, Suzuki H, Saito T, Osugi Y, Takunaga T, Kishimoto T. Human soluble IL-6 receptor: Its detection and enhanced release by HIV infection. J Immunol 1992;148:2175-80.
84. Lentz MR, Saltonstahl W. Apheresis of low molecular weight protein fraction and the onset of labor. J Clin Apheresis 1990; 5:62-7.
85. Lentz MR. Continuous whole blood ultra phereis procedure in patients with metastatic cancer. J Biol Resp Modif 1989;8: 511-27.
86. Lentz MR, Hubbard W, Fischer C. Low molecular weight protein apheresis and regression of breast cancer. Jpn J Apheresis 1997;16(1):107-14.
87. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K, Widmer MB, Blosch CM. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor Fc- fusion protein. New Engl J Med 1997; 337:141-7.
88. Murmn DH, Zlow M, Attwood JT, Mellor AL. Prevention of allogeneic fetal rejection by tryptophan calatrolesion. Science 1998;281:191-3.